Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- cisplatin
- Neo-Tab (neomycin)
Interactions between your drugs
CISplatin neomycin
Applies to: cisplatin, Neo-Tab (neomycin)
GENERALLY AVOID: Combining cisplatin and aminoglycosides may increase the risk of renal toxicity. Both cisplatin and aminoglycosides have been reported to cause renal magnesium wasting. The exact mechanism of the interaction is unknown.
MANAGEMENT: In patients currently receiving cisplatin therapy, the use of less nephrotoxic antimicrobials is preferable. If cisplatin and an aminoglycoside must be used together, renal function and serum magnesium should be monitored carefully.
References (7)
- Dentino M, Luft FC, Yum MN, et al. (1978) "Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man." Cancer, 41, p. 1274-81
- Hass A, Anderson L, Lad T (1983) "The influence of aminoglycosides on the nephrotoxicity of cis-diamminedichlorophatinum in cancer patients." J Infect Dis, 147, p. 363
- Patel R, Savage A (1979) "Symptomatic hypomagnesemia associated with gentamicin therapy." Nephron, 23, p. 50-2
- Stewart CF, Christensen ML, Crom WR, Evans WE (1984) "The effect of cisplatin therapy on gentamicin pharmacokinetics." Drug Intell Clin Pharm, 18, p. 512
- Blachley JD, Hill JB (1981) "Renal and electrolyte disturbances associated with cisplatin." Ann Intern Med, 95, p. 628-32
- Christensen ML, Stewart CF, Crom WR (1989) "Evaluation of aminoglycoside disposition in patients previously treated with cisplatin." Ther Drug Monit, 11, p. 631-6
- (2018) "Product Information. Arikayce (amikacin liposome)." Insmed Incorporated
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Loqtorzi
Loqtorzi (toripalimab-tpzi) is a PD-1 inhibitor medicine used for the treatment of advanced ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.